Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Lilly

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Lilly's 2013 sales performance.

Lilly

Teva will have to endure revenue 'trough' in 2019

Teva will have to endure revenue 'trough' in 2019

Ajovy has a particularly tough time as it will compete head-to-head with similar CGRP inhibitor products from Amgen/Novartis and Eli Lilly already on the market, with others from

FDA panel backs J&J’s new-class antidepressant

FDA panel backs J&J’s new-class antidepressant With just one other approved treatment for treatment-resistant in the US – Lilly’s Symbyax combination of olanzapine and Prozac active ingredient fluoxetine which was approved in 2009 – J&J has

Trulicity’s ascent lifts Lilly

Trulicity’s ascent lifts Lilly Diabetes treatment leads new product growth. Impressive growth from diabetes treatment Trulicity has helped Eli Lilly to post 7% growth in its full year results. ... This year will also see Lilly expand its ambitions in cancer, most notably with the $8bn

HTA guidance from NICE, the SMC and the AWMSG

17 Jan 2019. Ibrance and Verzenios gained NICE approval in November 2017, which means Lilly has some catching up to do.

Gilead awaits CEO and readouts to revive fortunes

Gilead awaits CEO and readouts to revive fortunes The once-a-day oral drug has already shown efficacy on a par with rival drugs from Lilly and AbbVie, and the phase 3 data could be crucial in deciding who

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...
Waiting room
Immunotherapy combination trials Q&A
By Chris Learn and Martin Lachs...

Infographics